What is a complete response letter (CRL) from the FDA?

A complete response letter, a CRL, is what the FDA sends a company when it has finished reviewing an application to market a drug and has decided not to approve it as submitted. The regulation that creates the letter defines it in a single sentence: the FDA sends one if the agency determines that it will not approve the application "in its present form". The application is not dead. It is not approved either.

Two things make the term confusing, and both are worth clearing before anything else.

The first is that "complete response" means something entirely different elsewhere in the same press releases. In trial results, a complete response is a patient whose tumour has disappeared, and a complete response rate is a headline number companies want you to see. A complete response letter has nothing to do with it. The name describes the FDA's action, not the outcome: the agency has responded completely to the application, rather than asking one more question.

The second is that headlines call a CRL a rejection, and it isn't quite one. A rejection would end the application. A CRL keeps it open and hands the company a to-do list. Whether that list takes two months or four years is the entire question, and the phrase "complete response letter" by itself does not tell you which.

What is actually in the letter?

The regulation is specific about the contents, and the specifics are the useful part.

The letter must describe "all of the specific deficiencies" the agency identified. That is an itemised list, not a general objection. It reflects the FDA's complete review of the data submitted, and it names any amendments the agency has not yet got to. And where the FDA can, it recommends actions the applicant might take to place the application "in condition for approval".

So a CRL is closer to a set of marked-up revisions than to a verdict. The deficiencies can be almost anything the review touches: the strength of the efficacy evidence, a safety question, the labelling, or the state of a factory the company does not own.

What does the company have to do, and how long does it take?

The same regulation gives the applicant exactly three options: resubmit the application addressing every deficiency, withdraw it, or ask the FDA for a hearing on whether there are grounds to deny approval. Almost every company resubmits.

The timing is where a CRL becomes something you can actually put in a calendar, because the resubmission clock is set by rule rather than by negotiation. The FDA classifies the resubmission, and the classification fixes the review period: a Class 1 resubmission starts a new two-month review cycle, and a Class 2 resubmission a new six-month cycle, each running from the date the FDA receives it. Roughly, Class 1 covers the tidy-up items: labelling, stability data, a safety update. Class 2 covers anything that requires real review, including new clinical data.

Capricor's cell therapy for the heart complications of Duchenne muscular dystrophy shows the mechanism end to end. The company received a CRL in July 2025 in which the FDA said the application did not meet the statutory requirement for substantial evidence of effectiveness, and cited the need for additional clinical data. That is the expensive kind: it cannot be answered with paperwork. Capricor put results from an ongoing phase 3 trial into the response, and on 10 March 2026 announced that the FDA had lifted the letter and classified the resubmission as Class 2, with a target action date of 22 August 2026. Six months, as written.

There is also an outer limit. If the company takes none of the three actions within one year, the FDA may treat that silence as a request to withdraw the application.

Why do two CRLs with the same name mean different things?

Compare Capricor's letter with the one Scholar Rock announced on 23 September 2025 for its spinal muscular atrophy drug apitegromab. The company's own headline said the CRL was solely related to observations at a third-party fill-finish facility, and the release stated that the observations were not specific to the drug and that the letter did not cite any other approvability concerns, including the efficacy and safety data.

Two letters, the same three words in the headline. One says the evidence that the drug works is insufficient. The other says a contract manufacturer's plant had inspection findings and the drug itself was never in question. Nothing in the term distinguishes them, but the press release almost always does, usually in the subheading, and the specific deficiency is the thing to read for before anything else.

Is a manufacturing CRL the easy one?

That is the natural conclusion from the pair above, and it is where the reasoning gets dangerous.

Unicycive received a CRL in June 2025 on its phosphate binder for dialysis patients, over deficiencies at a third-party manufacturing vendor. It resubmitted. On 30 June 2026 it announced a second CRL, based on the same third-party manufacturing deficiencies identified in the previous letter, and said the FDA had not yet inspected that vendor during the review of the resubmission. As with Scholar Rock, the agency raised nothing about the drug's efficacy or safety, and requested no additional data.

A year, two letters, and the clinical package was never the problem. The reason is structural: the deficiency sits inside a company the applicant does not own and cannot inspect, and it clears only when the FDA schedules and passes a facility inspection. No document tells you when that will happen. The company cannot tell you either, and a company that says it expects resolution quickly is describing a hope, not a date.

So the useful split is not clinical versus manufacturing. It is whether the fix is inside the company's control.

Can you read the letter yourself?

Increasingly, yes. The FDA now publishes complete response letters in a public database, which it says includes letters issued to sponsors as recently as 2025 and will grow as new letters are issued. Confidential commercial information and trade secrets are redacted first, so what you read is the letter minus the parts that identify proprietary methods. We keep that release browsable: all 444 letters in FDA's 26 August 2026 export, each with its full text, listed by year and company.

This is a real change in what a retail investor can see, and it is not yet a complete record. Coverage lags, and the database holds the agency's letter rather than the correspondence around it. Capricor's is a case in point. When the FDA posted its letter, the company said it had not been notified in advance and that the agency had not released the written response it had submitted, which it then published itself. You are reading one side of a conversation.

Reading one without getting ahead of it

• Find the named deficiency before anything else. The distance between "substantial evidence of effectiveness" and "observations at a fill-finish facility" is the distance between a new trial and an inspection.
• Ask who controls the fix. A deficiency at a contract manufacturer is not the applicant's to resolve on a schedule.
• Wait for the resubmission class. It converts the delay into two months or six, and until the FDA assigns it, any timeline is an estimate.
• Note what the letter did not say. Releases state plainly when the FDA raised nothing on efficacy or safety, and that absence is informative.
• Treat company language about expected timing as a forecast. The regulation sets the review clock; nothing sets the date a deficiency gets resolved.

A CRL is the FDA's itemised account of why an application is not approvable yet, and the item is what matters. The letter arrives after the trial results and, often, after an advisory committee has already voted — the last document in a sequence that starts with a topline press release and ends with a decision date that can pass in silence.

This is analysis, not investment advice.